Status:
UNKNOWN
Speech-based Digital Biomarker for Psychiatric Disease
Lead Sponsor:
Winterlight Labs
Conditions:
Speech
Psychiatric Disorder
Eligibility:
All Genders
18-95 years
Brief Summary
The general objectives of this study are to build a proof-of-concept, speech-based, digital biomarker for identifying the presence and tracking the severity of psychiatric disease.
Detailed Description
The purpose of this study is to gather longitudinal data to examine how speech features and symptoms change over different intervals of time and the reliability of repeated, high frequency test admini...
Eligibility Criteria
Inclusion
- Male and Female adults aged 18 to 95.
- English as a first language, or English as a second language with conversational proficiency.
- Own an iOS device (iPhone or iPad) and willing to install the study app.
- A reliable (cellular or WiFi) home internet connection and accessible email address
Exclusion
- Residence outside of Canada or the United States.
- Clinically significant vision impairment (corrected vision is acceptable).
- Clinically significant hearing impairment (use of hearing aids is acceptable)
Key Trial Info
Start Date :
April 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04851912
Start Date
April 27 2021
End Date
December 1 2023
Last Update
September 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Winterlight Labs
Toronto, Ontario, Canada, M4Y 1V8